Ask AI
ProCE Banner Activity

ExpressPoints
CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Individualizing Therapeutic Decisions to Improve Patient Outcomes

Slideset Download

Download this short summary slideset of key takeaway points from a live presentation on the latest data on treatment for patients with HR+/HER2- early breast cancer.

Released: July 09, 2021

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Javier Cortes, MD, PhD

Head, Breast Cancer Program
IOB Institute of Oncology
Madrid and Barcelona, Spain

Javier Cortes, MD, PhD: consultant/advisor: Abbvie, AstraZeneca, Bioasis, Biocon, BioInvent, Biontech, Bliss Biopharmaceutical, Boehringer Ingelheim, BridgeBio, Circle Pharma, Clovis Oncology, Daiichi Sankyo, Delcath Systems, Ellipses, Expres2ion Biotechnologies, GEMoaB, Gilead, Hexagon Bio, Hibercell, Jazz, Leuko, Lilly, Menarini, Merck Sharp & Dohme, Reveal Genomics, Roche, Scorpion Therapeutics, Seattle Genetics, Zymeworks; honoraria: AstraZeneca, Daiichi Sankyo, Eisai, Gilead, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Stemline, Zuellig; researcher (paid to institution): Ariad, AstraZeneca, Baxalta/Servier Affaires, Bayer Healthcare, Eisai, F. Hoffmann-La Roche, Guardant Health, Iqvia, Merck Sharp & Dohme, Pfizer, Piqur Therapeutics, Roche; individual publicly traded stock/stock options: Leuko; other financial or material support: AstraZeneca, Daiichi Sankyo, Eisai, Gilead, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Stemline; royalties or patent beneficiary: issued patent: Pharmaceutical Combinations of a PI3K Inhibitor and a Microtubule Destabilizing Agent (WO 2014/199294 A), licensed patent: HER2 as a Predictor of Response to Dual HER2 Blockade in the Absence of Cytotoxic Therapy (US 2019/0338368 A1).

Stephen R. D. Johnston, MA, FRCP, PhD

Professor of Breast Cancer Medicine
Breast Unit
Department of Medicine
Royal Marsden Hospital
London, United Kingdom

Sara M. Tolaney, MD, MPH

Chief, Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Sara M. Tolaney, MD, MPH: consultant/advisor/speaker: Aadi Bio, Atkis Oncology, Artios, Arvinas, AstraZeneca, Avenzo, Bayer, BeOne, Bicycle, BioNTech, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Celcuity, Samsung Bioepis, Circle Pharma, Cullinan Oncology, Daiichi Sankyo, eFFECTOR, Eisai, Genentech/Roche, Gilead, Hengrui USA, Jazz, Johnson & Johnson/Ambrx, Launch, Lilly, Menarini/Stemline, Merck, Mersana, Natera, Novartis, Olema, Pfizer/SeaGen, Reveal Genomics, Summit, Sumitovant Biopharma, Tango, Tempus, Zuellig; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Exelixis, Genentech/Roche, Gilead, Jazz, Lilly, Merck, Menarini/Stemline, NanoString, Novartis, OncoPep, Pfizer/SeaGen; other financial or material support: Arvinas, Gilead, Jazz, Lilly, Pfizer, Roche.